The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.43
Bid: 1.42
Ask: 1.44
Change: 0.00 (0.00%)
Spread: 0.02 (1.408%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.43
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monthly Valuation Update

14 Mar 2023 07:00

RNS Number : 7987S
RTW Venture Fund Limited
14 March 2023
 

LEI: 549300Q7EXQQH6KF7Z84

14 March 2023

RTW Venture Fund Limited

Monthly Valuation Update

-3.5% NAV movement

RTW Venture Fund Limited (the "Company") announces that the unaudited net asset value attributable to the ordinary shares of the Company at the close of business on 28 February 2023 (the "NAV") was US$334.6 million, or US$1.58 per ordinary share, a decrease of 3.5% from the previous month.

As of 28 February 2023, 23.2% of the total NAV was invested in privately held core portfolio companies and 48.7% of the total NAV was invested in public core portfolio companies, most of which were initiated as private investments. 28.5% was invested in other liquid public positions (which mirror holdings in RTW Investments, LP private funds) in lieu of holding cash for future core investments.

 

For Further Information:

RTW Investments, LP

+44 (0)20 7959 6361

Woody Stileman, Managing Director

 

 

 

Buchanan

+44 (0)20 7466 5107

Charles Ryland

 

Henry Wilson

 

George Beale

 

 

 

J.P. Morgan Cazenove

+44 (0)20 7742 4000

William Simmonds

 

Jérémie Birnbaum

 

James Bouverat (Sales)

 

 

BofA Securities

+44 (0) 20 7628 1000

Edward Peel

 

Kieran Millar

 

 

Elysium Fund Management Limited

+44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

 

Sadie Morrison, Managing Director

 

 

 

Morgan Stanley Fund Services USA LLC

+1 (914) 225 8885

 

 

 

Note:

1.

The NAV is determined by the Company's investment manager, RTW Investments, LP, in accordance with the Company's accounting policies. Investments by the Company in privately-held companies ("Private Portfolio Companies") have been valued at fair market value, taking into account the valuation prepared by Alvarez & Marsal Valuation Services LLC and the nature, facts and circumstances of the Private Portfolio Companies. Investments by the Company in companies listed on a public stock exchange (the "Public Portfolio Companies") have each been valued by reference to their market capitalisation as at close of business on 28 February 2023. The Company applies a valuation discount to its investments in Public Portfolio Companies that are subject to post-IPO lock-up provisions.

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVQXLFFXXLBBBF
Date   Source Headline
1st Feb 20247:00 amRNSTotal Voting Rights
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20247:00 amRNSUpdate on Arix Transaction
24th Jan 20247:00 amRNSTransaction in Own Shares
22nd Jan 20247:00 amRNSAcacia stake purchase & capital allocation plan
18th Jan 20247:00 amRNSTransaction in Own Shares
15th Jan 20247:00 amRNSMonthly Valuation Update, December Factsheet
10th Jan 20247:00 amRNSTransaction in Own Shares
8th Jan 20249:00 amRNSInvestment Update
5th Jan 20241:00 pmRNSPublication of a Prospectus
2nd Jan 20247:00 amRNSTotal Voting Rights
14th Dec 20237:00 amRNSMonthly Valuation Update, November Factsheet
6th Dec 20237:00 amRNSTransaction in Own Shares
1st Dec 20237:01 amRNSTotal Voting Rights
1st Dec 20237:00 amRNSTransaction in Own Shares
13th Nov 20237:00 amRNSPortfolio Company Update: CARGO Therapeutics, Inc
13th Nov 20237:00 amRNSTransaction in Own Shares
13th Nov 20237:00 amRNSMonthly Valuation Update, October Factsheet
9th Nov 20237:00 amRNSTransaction in Own Shares
8th Nov 20237:00 amRNSTransaction in Own Shares
1st Nov 202310:51 amEQSEdison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets
1st Nov 20237:06 amRNSRTW Biotech to acquire Arix Bioscience's assets
1st Nov 20237:05 amRNSTotal Voting Rights
16th Oct 20237:00 amRNSTransaction in Own Shares
13th Oct 20237:00 amRNSMonthly Valuation Update, Sep Factsheet, Q3 Letter
3rd Oct 20234:00 pmRNSDirector Declaration
2nd Oct 20237:00 amRNSTotal Voting Rights
18th Sep 20237:00 amRNSTransaction in Own Shares
15th Sep 20237:00 amRNSMonthly Valuation Update & August Factsheet
14th Sep 20237:00 amRNSUpdate on Largest Core Portfolio Position
13th Sep 20237:00 amRNSHalf-year Report
6th Sep 20237:00 amRNSTransaction in Own Shares
4th Sep 202311:00 amRNSAdditional Investment in Portfolio Company
14th Aug 20237:00 amRNSMonthly Valuation Update & July Factsheet
4th Aug 20237:30 amRNSEdison issues update on RTW Venture Fund (RTW)
1st Aug 202312:30 pmRNSTotal Voting Rights
21st Jul 20237:00 amRNSTransaction in Own Shares
17th Jul 20237:00 amRNSPortfolio Company Update: Apogee Therapeutics IPO
17th Jul 20237:00 amRNSMonthly Valuation Update, Factsheet & Q2 Letter
5th Jul 20237:00 amRNSCapital Allocation Plans from Prometheus Sale
30th Jun 202310:00 amRNSPortfolio Company Update: Tourmaline Bio
27th Jun 20237:00 amRNSChange of Name
21st Jun 20234:22 pmRNSResult of AGM
14th Jun 20237:00 amRNSMonthly Valuation Update & Factsheet
1st Jun 20237:00 amRNSNotice of AGM
12th May 20237:00 amRNSMonthly Valuation Update & Factsheet
9th May 20237:00 amRNSPortfolio Company Update: Acelyrin IPO
2nd May 20237:00 amRNSAnnual Financial Report
26th Apr 20237:00 amRNSNew Investment in Abdera Therapeutics
24th Apr 20232:39 pmRNSMarch Factsheet & First Quarter Letter

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.